AbbVie Submits sNDA to FDA for Venclexta-Acalabrutinib Combo in Frontline CLL

AbbVie has submitted a supplemental New Drug Software (sNDA) to the FDA for the approval of Venclexta (venetoclax) together with acalabrutinib in beforehand untreated sufferers with power lymphocytic leukemia (CLL).¹

AMPLIFY research helps time-limited oral mixture

The submission is supported by optimistic knowledge from the Section III AMPLIFY medical trial (NCT03836261). Within the research, the mix routine of Venclexta and acalabrutinib improved progression-free survival (PFS) in comparison with commonplace chemoimmunotherapy in beforehand untreated sufferers with CLL.

In a press launch, Svetlana Kobina, vice chairman, international medical affairs, oncology, AbbVie, mentioned: “This FDA submission marks a milestone for CLL therapy with the potential approval for the primary oral mixture routine of Venclexta and acalabrutinib for beforehand untreated sufferers with power blood most cancers. This new fixed-treatment period strategy may enable sufferers the chance for break day therapy, if authorised, and be probably practice-changing in frontline CLL care.”

Efficacy and security profile of the brand new mixture

Detailed knowledge from the AMPLIFY research had been shared on the 2024 American Society of Hematology Annual Assembly.

• Outcomes from AMPLIFY demonstrated {that a} fixed-duration mixture of Venclexta and acalabrutinib diminished the danger of illness development or loss of life by 35% in comparison with chemoimmunotherapy (HR 0.65; 95% CI: 0.49–0.87; p=0.004).
• The protection profile of the mix was in line with the identified profiles of every agent when used individually.
• Frequent adversarial occasions of any grade included neutropenia, bleeding, and COVID-19 an infection.
• Grade 3 or larger neutropenia was reported in 26.8% of sufferers receiving the mix therapy.
• Tumor lysis syndrome occurred sometimes, with any-grade occasions seen in simply 0.3% of sufferers on the Venclexta–acalabrutinib routine versus 3.1% within the chemoimmunotherapy group.
• No new security considerations emerged within the AMPLIFY research.

Interim AMPLIFY findings

An interim evaluation of AMPLIFY was printed in The New England Journal of Medication (NEJM) earlier in February. The multicenter, open-label trial randomized a complete of 867 sufferers 1:1:1 throughout three arms: 291 had been assigned to obtain acalabrutinib plus venetoclax, 286 acalabrutinib-venetoclax–obinutuzumab, and 290 chemoimmunotherapy.²

“On this interim evaluation of the AMPLIFY trial in match sufferers with beforehand untreated CLL, fixed-duration acalabrutinib–venetoclax (with or with out obinutuzumab) considerably extended progression-free survival as in contrast with chemoimmunotherapy,” the research authors wrote. “Outcomes for progression-free survival counsel that the good thing about including obinutuzumab to acalabrutinib–venetoclax was most obvious within the subgroup with unmutated IGHV (immunoglobulin heavy-chain variable area), which had outcomes that had been much like these within the subgroup with mutated IGHV.”

CLL14 trial underpinned earlier Venclexta approval

Venclexta’s newest FDA approval within the CLL area got here in Might 2019 when it was cleared as a part of a mix routine alongside Gazyva (obinutuzumab). This approval was primarily based on knowledge from the potential, multicenter, open-label, randomized Section III CLL14 trial (NCT02242942), which confirmed that sufferers who acquired the routine of Venclexta and Gazyva achieved superior PFS in comparison with those that acquired chlorambucil plus obinutuzumab.³

• After a median follow-up of 28 months, therapy with Venclexta plus obinutuzumab diminished the danger of illness development or loss of life by 67% in comparison with the mix of chlorambucil and obinutuzumab (HR 0.33; 95% CI: 0.22–0.51; p
• The mix of Venclexta and obinutuzumab additionally led to considerably larger charges of minimal residual illness (MRD) negativity, a secondary endpoint indicating deep remission.
• Three months post-treatment, MRD negativity in bone marrow was achieved in 57% of sufferers receiving Venclexta plus obinutuzumab versus 17% within the chlorambucil group (p
• In peripheral blood, MRD negativity was seen in 76% of sufferers within the Venclexta arm, in comparison with 35% with chlorambucil plus obinutuzumab (p

References

1. AbbVie Submits for U.S. FDA Approval of Mixture Therapy of VENCLEXTA® (venetoclax) and Acalabrutinib for Beforehand Untreated Sufferers with Continual Lymphocytic Leukemia (CLL). Information launch. AbbVie. July 29, 2025. Accessed July 29, 2025. https://information.abbvie.com/2025-07-29-AbbVie-Submits-for-U-S-FDA-Approval-of-Mixture-Therapy-of-VENCLEXTA-R-venetoclax-and-Acalabrutinib-for-Beforehand-Untreated-Sufferers-with-Continual-Lymphocytic-Leukemia-CLL

2. Jennifer R. Brown, MD, et al., Fastened-Length Acalabrutinib Mixtures in Untreated Continual Lymphocytic Leukemia. New England Journal of Medication. https://www.nejm.org/doi/full/10.1056/NEJMoa2409804. (2025)

3. AbbVie Proclaims US FDA Approval of VENCLEXTA® (venetoclax) as a Chemotherapy-Free Mixture Routine for Beforehand Untreated Continual Lymphocytic Leukemia Sufferers. Information launch. AbbVie. Might 15, 2019. Accessed July 29, 2025. https://information.abbvie.com/2019-05-15-AbbVie-Proclaims-US-FDA-Approval-of-VENCLEXTA-R-venetoclax-as-a-Chemotherapy-Free-Mixture-Routine-for-Beforehand-Untreated-Continual-Lymphocytic-Leukemia-Sufferers